MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
Columbia University Medical Center, New York, New York, United States
Harvard Medical School, Boston, Massachusetts, United States
UCLA, Los Angeles, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.